<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006368</url>
  </required_header>
  <id_info>
    <org_study_id>NOVARTIS-SMT-B151</org_study_id>
    <secondary_id>MCC-12275</secondary_id>
    <secondary_id>MCC-IRB-5473</secondary_id>
    <secondary_id>CDR0000068241</secondary_id>
    <secondary_id>NCI-G00-1857</secondary_id>
    <nct_id>NCT00006368</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver
      tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase I trial to study the effectiveness of yttrium Y 90 SMT 487 in treating
      patients who have refractory or recurrent cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of yttrium Y 90-SMT 487 in patients with
      recurrent malignant neoplasms that prove positive for somatostatin receptors. II. Determine
      the safety and lifetime serious adverse event profile of this regimen in these patients. II.
      Determine the antitumor effect and the effect of repeated administrations on the renal
      excretion pharmacokinetics of this regimen in these patients.

      OUTLINE: This is a dose escalation, multicenter study. Patients undergo octreotide
      scintigraphy to determine the location of somatostatin receptors. Patients then receive
      yttrium Y 90-SMT 487 IV over 15 minutes on day 1. Treatment continues every 6 weeks for up to
      4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6
      patients each are entered on course I (vertical dose escalation) and courses II, III, and IV
      (horizontal dose escalation). Cohorts receive escalating doses of yttrium Y 90-SMT 487 until
      the maximum tolerated dose (MTD) is determined. MTDs are determined for a single course and
      for 4 courses. The MTD is defined as the dose preceding that at which no more than 2 of 6
      patients experience dose limiting toxicities. Results of course I determine the dosage of
      subsequent courses. Patients are evaluated on days 2 and 7, and at weeks 4 and 6, following
      each injection of yttrium Y 90-SMT 487. Patients are followed at 12 and 18 months and then
      annually thereafter.

      PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Tumor</condition>
  <condition>Lung Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Neoplastic Syndrome</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90-edotreotide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed, progressive malignant
        neoplasm Clinical diagnosis of multiple endocrine neoplasia (MEN) types I and II allowed
        Tumors positive for somatostatin receptors by octreotide scintigraphy, such as: Pituitary
        Brain Endocrine pancreatic Lymphoma Carcinoid Melanoma Small cell lung Breast Disease not
        amenable to standard treatment OR Failed existing first and second line therapies (failed
        at least 1 regimen in the case of small cell lung cancer) Bone disease (no diffuse bone
        marrow involvement), pleural effusions, and ascites allowed

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Course I: Karnofsky 50-100%
        Courses II-IV: Karnofsky 30-100% Life expectancy: At least 6 months and no greater than 2.5
        years (for course I only) Hematopoietic: Course I: Hemoglobin at least 8 g/dL WBC at least
        3,500/mm3 Platelet count at least 100,000/mm3 Courses II-IV: WBC at least 3,000/mm3
        Platelet count at least 75,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than
        1.7 mg/dL OR Creatinine clearance at least 40 mL/min Cardiovascular: No history of
        congestive heart failure unless ejection fraction at least 40% Other: Not pregnant or
        nursing Negative pregnancy test Fertile patients must use effective contraception during
        and for 6 months after study No other concurrent malignancy except MEN I or II or squamous
        cell skin cancer No concurrent significant, uncontrolled, medical, psychiatric, or surgical
        condition that would preclude study (course 1)

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy Greater than 4 weeks
        since prior chemotherapy Endocrine therapy: At least 4 months since prior long acting
        somatostatin analogue Concurrent hormonal therapy (except somatostatin analogues) allowed
        if started at least 2 months previously Radiotherapy: Greater than 4 weeks since prior
        radiotherapy No prior radiotherapy to at least 25% of bone marrow Surgery: Greater than 4
        weeks since prior surgery Other: Greater than 4 weeks since prior investigational drugs No
        other concurrent investigational drug therapy No other concurrent antineoplastic therapy
        Concurrent bisphosphonates allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry K. Kvols, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>April 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2004</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>insulinoma</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>ACTH-producing pituitary tumor</keyword>
  <keyword>prolactin-producing pituitary tumor</keyword>
  <keyword>growth hormone-producing pituitary tumor</keyword>
  <keyword>recurrent pituitary tumor</keyword>
  <keyword>TSH producing pituitary tumor</keyword>
  <keyword>nonfunctioning pituitary tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edotreotide</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

